Cadence Capital Management’s Champions Oncology CSBR Stock Holding History

Cadence Capital Management’s Portfolio CSBR Stock Details CSBR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	$370K	Sell	40,044 -192,226	-83%	-$1.71M	0.09%	201
2020 Q2	$2.22M	Buy	232,270 +9,956	+4%	+$84.9K	0.32%	62
2020 Q1	$1.65M	Sell	222,314 -11,828	-5%	-$82.7K	0.28%	96
2019 Q4	$1.95M	Sell	234,142 -13,955	-6%	-$86.1K	0.21%	145
2019 Q3	$1.4M	Sell	248,097 -16,394	-6%	-$106K	0.2%	198
2019 Q2	$2.07M	Sell	264,491 -8,844	-3%	-$77.6K	0.21%	158
2019 Q1	$2.68M	Buy	273,335 +150,325	+122%	+$1.5M	0.24%	113
2018 Q4	$961K	Buy	+123,010	New	+$1.41M	0.1%	276

Other funds holding CSBR

BPI

Battery Partners IX Boston, Massachusetts $22.4M AUM 27.71% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TAM

Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

EIM

Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

MAG

Millrace Asset Group Berwyn, Pennsylvania $98.4M AUM 63.71% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Cadence Capital Management's CSBR Position: Q3 2020 in Review

Cadence Capital Management reduced its Champions Oncology (CSBR) stake by 83% in Q3 2020, selling an estimated $1.71M and leaving 40,044 shares worth $370K. The position accounts for 0.09% of the portfolio, ranked #201.

Cadence Capital Management first reported a position in CSBR in Q4 2018 and has held it in 8 quarters since. The position peaked at $2.68M in Q1 2019. 46 funds tracked by Wall St. Rank hold CSBR as of Q3 2020.

Cadence Capital Management held 40,044 shares of Champions Oncology worth $370K as of Q3 2020.
Cadence Capital Management sold 192,226 Champions Oncology shares in Q3 2020, an estimated $1.71M.
Champions Oncology made up 0.09% of Cadence Capital Management's portfolio in Q3 2020, its #201 holding.
Cadence Capital Management first reported a position in Champions Oncology in Q4 2018 and has held it in 8 quarters since.
Cadence Capital Management's Champions Oncology position peaked at $2.68M in Q1 2019.
46 funds tracked by Wall St. Rank held Champions Oncology as of Q3 2020.

Based on Cadence Capital Management's 13F filing for Q3 2020, filed 16 Oct 2020.